ArticleJournal of clinical biochemistry and nutrition2016

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib.

Naoki Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.